Evidence map›Paper›PMID 27704333›Full record

SynthesisJournal of thrombosis and thrombolysis2017

Risk of intracranial hemorrhage associated with therapeutic anticoagulation for venous thromboembolism in cancer patients: a systematic review and meta-analysis.

Cristhiam M Rojas-Hernandez, Thein Hlaing Oo, Herney Andrés García-Perdomo

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of thrombosis and thrombolysis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Cerebrovascular and Peripheral Vascular Complications in Cancer Patients.Current neurology and neuroscience reports · 2025
    Review
  2. Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2021
    Article
  3. Article
  4. Article
  5. Neurological and Medical Complications in Brain Tumor Patients.Current neurology and neuroscience reports · 2020
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Cristhiam M Rojas-HernandezSection of Benign Hematology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., suite 1464, Houston, TX, 77030, USA. cmrojas@mdanderson.org.
Thein Hlaing OoSection of Benign Hematology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., suite 1464, Houston, TX, 77030, USA.
Herney Andrés García-PerdomoDepartment of Urology, Universidad del Valle, Cali, Colombia.
The University of Texas MD Anderson Cancer Center · USUniversidad del Valle · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intracranial hemorrhage (ICH) in cancer patients can result from tumor bleeding and from antitumor and anticoagulation therapy. The effect of anticoagulation on the incidence of ICH in cancer patients has not been quantified. Our objective was to determine the risk of intracranial hemorrhage associated with anticoagulation therapy for cancer-associated venous thromboembolism (VTE). Systematic review and meta-analysis of studies assessing the safety of anticoagulation therapy in patients with cancer-associated VTE. The primary endpoint of interest was the incidence of ICH and secondary outcomes included all major bleeding, and the time to ICH and major bleeding. After identifying 595 studies, five studies and 2089 patients were included in the analyses. We found that the relative risk (RR) for ICH was 0.494, 95 % CI (0.105-2.331) when low molecular weight heparin (LMWH) with vitamin K antagonist (VKA) anticoagulants were compared. No statistically significant differences in risk were measured. The risk of major bleeding using any type of anticoagulation therapy in patients with cancer-associated VTE was RR 0.853, 95 % CI (0.549, 1.327). After meta-analytic review of data published through August 2015, we conclude that therapeutic anticoagulation with LMWH given ≤6 months does not increase the risk of ICH in cancer patients compared to VKA. The risk of ICH in cancer patients is also similar to that of non-cancer patients. Available data were insufficient to determine if the ICH risk increase changes when the duration of anticoagulation is >6 months.

Indexed as

AnticoagulantsHeparin, Low-Molecular-WeightHumansIntracranial HemorrhagesNeoplasmsRiskVenous ThromboembolismVitamin KAnticoagulantsHeparin, Low-Molecular-WeightVitamin KAnticoagulationCancerIntracranial hemorrhageVenous thromboembolism

Identifiers

PMID27704333
OpenAlexW2529639159

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.